Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: A historical perspective

Frontiers in Pharmacology

Volumn 9, Issue JAN, 2019, Pages

  Aapro, Matti ^a   Gascón, Pere ^b   Patel, Kashyap ^c   Rodgers, George M ^d   Fung, Selwyn ^e   Arantes, Luiz H ^e   Wish, Jay ^f  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Carolina Blood and Cancer Care Associates   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e PFIZER INC   (United States)

^f INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

Anemia; Biosimilars; Cancer; Erythropoiesis stimulating agents; Kidney disease

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER SURVIVAL; CHRONIC KIDNEY FAILURE; COST CONTROL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MALIGNANT NEOPLASM; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW;

EID: 85065502813     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2018.01498     Document Type: Review

References (71)

1. Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascon, P., Glaspy, J., et al. (2018a). Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. 29, iv96-iv110. doi: 10.1093/annonc/mdx758
2. Aapro, M., Krendyukov, A., Schiestl, M., and Gascon, P. (2018b). Epoetin biosimilars in the treatment of chemotherapy-induced anemia: 10 years' experience gained. BioDrugs 32, 129-135. doi: 10.1007/s40259-018-0262-9
3. Aapro, M., Cornes, P., Sun, D., and Abraham, I. (2012). Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther. Adv. Med. Oncol. 4, 95-105. doi: 10.1177/1758834012444499
4. Abraham, I., Han, L., Sun, D., MacDonald, K., and Aapro, M. (2014). Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol. 10, 1599-1609. doi: 10.2217/fon.14.43
5. Bennett, C. L., Luminari, S., Nissenson, A. R., Tallman, M. S., Klinge, S. A., McWilliams, N., et al. (2004). Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351, 1403-1408. doi: 10.1056/NEJMoa040528
6. Bennett, C. L., McKoy, J. M., Henke, M., Silver, S. M., MacDougall, I. C., Birgegard, G., et al. (2010). Reassessments of ESAs for cancer treatment in the US and Europe. Oncology 24, 260-268.
7. Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., et al. (1998). The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590. doi: 10.1056/NEJM199808273390903
8. Blackstone, E. A., and Joseph, P. F. (2013). The economics of biosimilars. Am. Health Drug Benefits 6, 469-478.
9. Bohlius, J., Langensiepen, S., Schwarzer, G., Seidenfeld, J., Piper, M., Bennet, C., et al. (2004). Erythropoietin for patients with malignant disease. Cochrane Database Syst. Rev. CD003407. doi: 10.1002/14651858.CD003407.pub2
10. Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., et al. (2009). Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst. Rev. CD007303. doi: 10.1002/14651858.CD007303.pub2
11. Bokemeyer, C., Aapro, M. S., Courdi, A., Foubert, J., Link, H., Osterborg, A., et al. (2004). EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer 40, 2201-2216. doi: 10.1016/j.ejca.2004.07.015
12. Bokemeyer, C., Aapro, M. S., Courdi, A., Foubert, J., Link, H., Osterborg, A., et al. (2007). EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur. J. Cancer 43, 258-270. doi: 10.1016/j.ejca.2006.10.014
13. Bunn, H. F. (2013). Erythropoietin. Cold Spring Harb. Perspect. Med. 3:a011619. doi: 10.1101/cshperspect.a011619
14. Cella, D., and Bron, D. (1999). The effect of epoetin alfa on quality of life in anemic cancer patients. Cancer Pract. 7, 177-182. doi: 10.1046/j.1523-5394.1999.74008.x
15. Center for Medicare and Medicaid Services. (2007). National Coverage Determination (NCD) for Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions (110.21). Baltimore, MD: US Department of Health and Human Services. Available at: https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDid=322&ncdver=1 [accessed February 21, 2018].
16. Drueke, T. B., Locatelli, F., Clyne, N., Eckardt, K. U., Macdougall, I. C., Tsakiris, D., et al. (2006). Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084. doi: 10.1056/NEJMoa062276
17. Elliott, S., Pham, E., and Macdougall, I. C. (2008). Erythropoietins: a common mechanism of action. Exp. Hematol. 36, 1573-1584. doi: 10.1016/j.exphem.2008.08.003
18. Erslev, A. (1953). Humoral regulation of red cell production. Blood 8, 349-357.
19. Evans, R. W., Rader, B., and Manninen, D. L. (1990). The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 263, 825-830. doi: 10.1001/jama.1990.03440060071035
20. Fujisaka, Y., Sugiyama, T., Saito, H., Nagase, S., Kudoh, S., Endo, M., et al. (2011). Randomised, phase III trial of epoetin-beta to treat chemotherapy-induced anaemia according to the EU regulation. Br. J. Cancer 105, 1267-1272. doi: 10.1038/bjc.2011.395
21. Hagerty, K. (2008). Continued regulatory actions affecting the use of erythropoiesis-stimulating agents. J. Oncol. Pract. 4, 267-270. doi: 10.1200/JOP.0863501
22. Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K. D., Schilcher, B., et al. (2003). Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255-1260. doi: 10.1016/S0140-6736(03)14567-9
23. Jabbour, E., Kantarjian, H. M., Koller, C., and Taher, A. (2008). Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112, 1089-1095. doi: 10.1002/cncr.23280
24. Jacobson, L. O., Goldwasser, E., Fried, W., and Plzak, L. (1957). Role of the kidney in erythropoiesis. Nature 179, 633-634. doi: 10.1038/179633a0
25. Kidney Disease Improving Global Outcomes [KDIGO] (2012). KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Available at: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf [accessed October 30, 2018].
26. Koulouridis, I., Alfayez, M., Trikalinos, T. A., Balk, E. M., and Jaber, B. L. (2013). Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am. J. Kidney Dis. 61, 44-56. doi: 10.1053/j.ajkd.2012.07.014
27. Lammerich, A., Balcke, P., Bias, P., Mangold, S., and Wiesholzer, M. (2016). Cardiovascular morbidity and pure red cell aplasia associated with epoetin theta therapy in patients with chronic kidney disease: a prospective, noninterventional, multicenter cohort study. Clin. Ther. 38, 276-287.e4. doi: 10.1016/j.clinthera.2015.11.018
28. Lammers, P., Criscitiello, C., Curigliano, G., and Jacobs, I. (2014). Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals 7, 943-953. doi: 10.3390/ph7090943
29. Leyland-Jones, B., and BEST Investigators and Study Group (2003). Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4, 459-460. doi: 10.1016/S1470-2045(03)01163-X
30. Leyland-Jones, B., Bondarenko, I., Nemsadze, G., Smirnov, V., Litvin, I., Kokhreidze, I., et al. (2016). A randomized, open-label, multicenter, phase iii study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J. Clin. Oncol. 34, 1197-1207. doi: 10.1200/JCO.2015.63.5649
31. Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., et al. (2005). Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23, 5960-5972. doi: 10.1200/JCO.2005.06.150
32. Locatelli, F., Aljama, P., Canaud, B., Covic, A., De Francisco, A., Macdougall, I. C., et al. (2010). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with aranesp therapy (TREAT) study. Nephrol. Dial. Transplant. 25, 2846-2850. doi: 10.1093/ndt/gfq336
33. Lodish, H., Flygare, J., and Chou, S. (2010). From stem cell to erythroblast: regulation of red cell production at multiple levels by multiple hormones. IUBMB Life 62, 492-496. doi: 10.1002/iub.322
34. Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegard, G., Bokemeyer, C., Gascon, P., et al. (2004). The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40, 2293-2306. doi: 10.1016/j.ejca.2004.06.019
35. Luksenberg, H., Weir, A., and Wager, R. (2004). Safety Concerns Associated with Aranesp (Darbepoetin Alfa) Amgen, Inc. and Procrit (Epoetin Alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy. Silver Spring, MD: US Food and Drug Administration. Available at: https://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B2_04_FDAAranesp-Procrit.htm [accessed February 7, 2018].
36. Ma, J. Z., Ebben, J., Xia, H., and Collins, A. J. (1999). Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Nephrol. 10, 610-619. doi: 10.1046/j.1525-139x.2000.00036.x
37. Macdougall, I. C., Casadevall, N., Locatelli, F., Combe, C., London, G. M., Di Paolo, S., et al. (2015). Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol. Dial. Transplant. 30, 451-460. doi: 10.1093/ndt/gfu297
38. McKoy, J. M., Stonecash, R. E., Cournoyer, D., Rossert, J., Nissenson, A. R., Raisch, D. W., et al. (2008). Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 48, 1754-1762. doi: 10.1111/j.1537-2995.2008.01749.x
39. Michallet, M., and Losem, C. (2016). Biosimilar epoetin zeta in oncology and haematology: development and experience following 6 years of use. Acta Haematol. 135, 44-52. doi: 10.1159/000438976
40. Mikhail, H., Brown, C., Williams, J. A., Mathrani, V., Shrivastava, R., Evans, J., et al. (2017). Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 18:345. doi: 10.1186/s12882-017-0688-1
41. Moebus, V., Jackisch, C., Schneeweiss, A., Huober, J., Lueck, H. J., du Bois, A., et al. (2013). Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J. Natl. Cancer Inst. 105, 1018-1026. doi: 10.1093/jnci/djt145
42. Mountzios, G., Aravantinos, G., Alexopoulou, Z., Timotheadou, E., Matsiakou, F., Christodoulou, C., et al. (2016). Lessons from the past: long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia. Mol. Clin. Oncol. 4, 211-220. doi: 10.3892/mco.2015.693
43. Nagarkar, R., Gascón, P., Šmakal, M., Syrigos, K. N., Barrios, C. H., Sánchez, J. C., et al. (2018). “A double-blind, randomized, placebo-controlled phase 3 noninferiority study of darbepoetin alfa for anemia in advanced NSCLC,” in Proceedings of the IASLC 19th World Conference on Lung Cancer; Sept 23-26, Toronto. doi: 10.1016/j.jtho.2018.08.325
44. Nagel, S., Kellner, O., Engel-Riedel, W., Guetz, S., Schumann, C., Gieseler, F., et al. (2011). Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Clin. Lung Cancer 12, 62-69. doi: 10.3816/CLC.2011.n.009
45. Nathan, D. G., Schupak, E., Stohlman, F. Jr., and Merrill, J. P. (1964). Erythropoiesis in anephric man. J. Clin. Invest. 43, 2158-2165. doi: 10.1172/JCI105089
46. National Comprehensive Cancer Network [NCCN] (2018). Cancer- and Chemotherapy-Induced Anemia (Version 3.2018). Available: https://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf [accessed October 30, 2018].
47. National Institute for Health and Care Excellence [NICE] (2015). NICE Guideline (NG-8): Chronic Kidney Disease: Managing Anemia. Available: https://www.nice.org.uk/guidance/ng8/chapter/1-Recommendations [accessed October 31, 2018].
48. National Kidney Foundation Dialysis Outcomes Quality Initiative [NKF-DOQI] (1997). NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am. J. Kidney Dis. 30, S192-S240.
49. Nitz, U., Gluz, O., Zuna, I., Oberhoff, C., Reimer, T., Schumacher, C., et al. (2014). Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann. Oncol. 25, 75-80. doi: 10.1093/annonc/mdt505
50. Noxon, V., Bennett, C. L., and Wu, J. (2014). The reduction of erythropoietin stimulating agent (ESA) use due to the FDA black box warning. Blood 124:1276.
51. Parfrey, P. S., Foley, R. N., Wittreich, B. H., Sullivan, D. J., Zagari, M. J., and Frei, D. (2005). Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J. Am. Soc. Nephrol. 16, 2180-2189. doi: 10.1681/ASN.2004121039
52. Pfeffer, M. A., Burdmann, E. A., Chen, C. Y., Cooper, M. E., de Zeeuw, D., Eckardt, K. U., et al. (2009). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032. doi: 10.1056/NEJMoa0907845
53. Porter, J. B. (2001). Practical management of iron overload. Br. J. Haematol. 115, 239-252. doi: 10.1046/j.1365-2141.2001.03195.x
54. Quintiles IMS (2017). The Impact of Biosimilar Competition in Europe. Available: http://ec.europa.eu/DocsRoom/documents/23102 [accessed October 26, 2017]
55. Rizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L., et al. (2010). American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116, 4045-4059. doi: 10.1182/blood-2010-08-300541
56. Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., et al. (2002). Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100, 2303-2320. doi: 10.1182/blood-2002-06-1767
57. Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., et al. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111, 25-41. doi: 10.1182/blood-2007-08-109488
58. Rodgers, G. M. (2012). A perspective on the evolution of management of cancer- and chemotherapy-induced anemia. J. Natl. Compr. Cancer Netw. 10, 434-437. doi: 10.6004/jnccn.2012.0044
59. Schrijvers, D., De Samblanx, H., Roila, F., and ESMO Guidelines Working Group (2010). Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann. Oncol. 21(Suppl. 5), v244-v247. doi: 10.1093/annonc/mdq202
60. Seetasith, A. (2013). Impacts of Black Box Warning, National Coverage Determination, and Risk Evaluation and Mitigation Strategies on The Inpatient On-Label and Off-Label Use of Erythropoiesis-Stimulating Agents. Ph.D. Thesis, Graduate School, Virginia Commonwealth University, Richmond, VA. doi: 10.1016/j.jval.2013.03.614
61. Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., et al. (2006). Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098. doi: 10.1056/NEJMoa065485
62. Singh, S. C., and Bagnato, K. M. (2015). The economic implications of biosimilars. Am. J. Manag. Care 21, s331-s340.
63. Socinski, M. A., Curigliano, G., Jacobs, I., Gumbiner, B., MacDonald, J., and Thomas, D. (2015). Clinical considerations for the development of biosimilars in oncology. MAbs 7, 286-293. doi: 10.1080/19420862.2015.1008346
64. Stauffer, M. E., and Fan, T. (2014). Prevalence of anemia in chronic kidney disease in the United States. PLoS One 9:e84943. doi: 10.1371/journal.pone.0084943
65. Szczech, L. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S., Califf, R. M., et al. (2008). Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 74, 791-798. doi: 10.1038/ki.2008.295
66. Untch, M., von Minckwitz, G., Konecny, G. E., Conrad, U., Fett, W., Kurzeder, C., et al. (2011). PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann. Oncol. 22, 1999-2006. doi: 10.1093/annonc/mdq713
67. US Food and Drug Administration (2007a). FDA Advisory Committee Briefing Document. Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety Risk Management Committee. Silver Spring, MD: U.S. Food and Drug Administration.
68. US Food and Drug Administration (2007b). FDA Alert. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) [Aranesp (Darbepoetin), Epogen (Epoetin Alfa), and Procrit (Epoetin Alfa)]. Available at: https://wayback.archiveit.org/7993/20170723113601/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126481.htm [accessed November 15, 2017]
69. US Food and Drug Administration (2011). FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm259639.htm [accessed February 7, 2018]
70. US Food and Drug Administration (2017). Information on Erythropoiesis-Stimulating Agents (ESA) Epoetin Alfa (marketed as Procrit, Epogen), Darbepoetin Alfa (marketed as Aranesp). Silver Spring, MD: US Food and Drug Administration. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm109375.htm [accessed February 7, 2018].
71. Xu, H., Xu, L., Page, J. H., Cannavale, K., Sattayapiwat, O., Rodriguez, R., et al. (2016). Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010-2013. Clin. Epidemiol. 8, 61-71. doi: 10.2147/CLEP.S89480